The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Mark W. Lingen and Elizabeth Blair.
Connection Strength

0.605
  1. Mucoepidermoid Carcinoma: A Comparison of Histologic Grading Systems and Relationship to MAML2 Rearrangement and Prognosis. Am J Surg Pathol. 2019 07; 43(7):885-897.
    View in: PubMed
    Score: 0.177
  2. Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
    View in: PubMed
    Score: 0.055
  3. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
    View in: PubMed
    Score: 0.053
  4. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566.
    View in: PubMed
    Score: 0.052
  5. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 10 01; 30(10):1673.
    View in: PubMed
    Score: 0.045
  6. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
    View in: PubMed
    Score: 0.043
  7. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9.
    View in: PubMed
    Score: 0.036
  8. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16.
    View in: PubMed
    Score: 0.035
  9. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41.
    View in: PubMed
    Score: 0.031
  10. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFeradeā„¢ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
    View in: PubMed
    Score: 0.028
  11. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43.
    View in: PubMed
    Score: 0.027
  12. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.